Adverse events during treatments
| Adverse event | Grade1* | Grade2 | Grade3 | Grade4 | Total |
|---|---|---|---|---|---|
| RCCEP | 7 | 0 | 0 | 0 | 7 (17.9%) |
| Fatigue and weakness | 5 | 0 | 0 | 0 | 5 (12.8%) |
| Digestive dysfunction | 3 | 0 | 0 | 0 | 3 (7.7%) |
| Fever | 3 | 0 | 0 | 0 | 3 (7.7%) |
| Anemia | 3 | 0 | 0 | 0 | 3 (7.7%) |
| Leukopenia | 2 | 0 | 1 | 0 | 3 (7.7%) |
| Pain | 2 | 0 | 0 | 0 | 2 (5.1%) |
| Hypertension | 1 | 0 | 0 | 1 | 2 (5.1%) |
| Rash | 2 | 0 | 0 | 0 | 2 (5.1%) |
| HFSR | 1 | 1 | 0 | 0 | 2 (5.1%) |
| Hypohepatia | 1 | 1 | 0 | 0 | 2 (5.1%) |
| Diarrhea | 1 | 0 | 0 | 0 | 1 (2.6%) |
| Albuminuria | 1 | 0 | 0 | 0 | 1 (2.6%) |
| Limb edema | 1 | 0 | 0 | 0 | 1 (2.6%) |
| Anorexia | 1 | 0 | 0 | 0 | 1 (2.6%) |
| Hypothyroidism | 1 | 0 | 0 | 0 | 1 (2.6%) |
*According to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, version 3.0). RCCEP, reactive capillary hyperplasia; HFSR, hand and foot syndrome.